At the 2019 ISPOR conference, Jeroen Jansen sat down with AJMC to explain the current state of value assessment and how by putting patients at the frontend of analysis, we can better quantify the value of a treatment. Watch the brief interview here.
Devin Incerti sat down with the AJMC media team at the 2019 ISPOR conference to discuss how value is context-specific and therefore value assessment should be too. Watch the interview here.
After the release of the public comments for IVI-NSCLC, Managed Healthcare Executive took a look at IVI's open-source model focusing on non-small lung cancer and how it will bring healthcare executives insight into value that otherwise wouldn't exist with traditional models. Read the full article here.
In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions [...]
Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model - our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI's mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to [...]
In the wake of this year's ISPOR conference, IVI's Executive Director, Jennifer Bright, reflects on how to move value assessment from a static snapshot in time to an active learning approach. She discusses the following five steps to improving value assessment: Take the transparency challenge. Embrace flexibility. Allow for iteration. Improve incorporation of non-clinical data. [...]
The IVI team sat down with the Journal of Clinical Pathways while at ISPOR for an in-depth discussion about why advanced value assessment is needed and how it’s progressing. The team also discussed the QALY – what it is and whether it can be improved. To listen to the podcast or read the transcript, click [...]
As part of the public input process, IVI submitted comments on the Institute for Clinical and Economic Review’s (ICER) 2020 Value Assessment Framework. In May, ICER invited public comments as part of their process to update methods that underpin ICER reports. In summary, IVI wrote that value assessment must: • Provide flexible models that can [...]
After the panel presentation, “The Controversial QALY: Is There a Middle Ground in the Debate?” was wrapped up at ISPOR, AJMC deputy editor, Jaime Rosenberg, sat down with IVI's Jennifer Bright and Lou Garrison (assistant director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington) to drill down further into the [...]
IVI Executive Director, Jennifer Bright, moderated a fascinating panel discussion on the quality-adjusted life-year (QALY) and whether there is room for a middle ground in the discussion about its merits and shortcomings. Lou Garrison, PhD, Assistant Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington; Eleanor M. Perfetto, PhD, MS, [...]
